Kurt Zimmermann

USPTO Granted Patents = 26 (Patent Applications = 14)

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 5 (Patent Applications = 8)

Average Co-Inventor Count = 7.1

ph-index = 5

Forward Citations = 111(Granted Patents)

Company Filing History:

17 out of 3,681

Bristol-myers Squibb Compnay

patents

9 out of 57

Arvinas Operations, Inc.

where one patent can have more than one assignee

Years Active: 2003-2025

Loading Chart...

26 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12441708 - Cereblon ligands and bifunctional compounds comprising the same (2025-10-14),

2. 12264157 - Compounds and methods for the enhanced degradation of targeted proteins (2025-04-01),

3. 11986531 - Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides (2024-05-21),

4. 11964945 - Compounds and methods for the targeted degradation of androgen receptor (2024-04-23),

5. 11512083 - Compounds and methods for the enhanced degradation of targeted proteins (2022-11-29),

6. 11427548 - Compounds and methods for the targeted degradation of androgen receptor (2022-08-30),

7. 11236051 - Compounds and methods for the targeted degradation of androgen receptor (2022-02-01),

8. 10994015 - EGFR proteolysis targeting chimeric molecules and associated methods of use (2021-05-04),

9. 10730870 - Compounds and methods for the enhanced degradation of targeted proteins (2020-08-04),

10. 10550125 - Prodrugs of imidazotriazine compounds as CK2 inhibitors (2020-02-04),

11. 9556178 - Imidazotriazinecarbonitriles useful as kinase inhibitors (2017-01-31),

12. 9273057 - Imidazotriazinecarbonitriles useful as kinase inhibitors (2016-03-01),

13. 8940736 - Imidazotriazinecarbonitriles useful as kinase inhibitors (2015-01-27),

14. 8815840 - Carbazole and carboline kinase inhibitors (2014-08-26),

15. 8592579 - Pyrrolotriazine kinase inhibitors (2013-11-26),

Title: **Kurt Zimmermann: Innovator in Targeted Degradation Compounds**

Introduction

Kurt Zimmermann, based in Durham, Connecticut, is a prolific inventor with a remarkable portfolio of 24 patents. His innovative work primarily focuses on developing compounds for the targeted degradation of proteins, particularly in the context of serious diseases. His contributions have significantly advanced the field of pharmaceutical research and drug development.

Latest Patents

Zimmermann's latest patents include significant advancements in compounds and methods for the targeted degradation of Rapidly Accelerated Fibrosarcoma (RAF) polypeptides. These bifunctional compounds are designed to modulate proteins such as c-RAF, A-RAF, and B-RAF by linking them to E3 ubiquitin ligases, ultimately facilitating their degradation. This approach shows promising pharmacological activity, providing therapeutic potential for conditions resulting from the accumulation of these target proteins.

Additionally, he has developed compounds for the targeted degradation of the Androgen Receptor. These compounds also utilize a bifunctional mechanism to bring the Androgen Receptor into the vicinity of the E3 ubiquitin ligase, leading to its degradation and inhibition. Such strategies open new avenues for treatment of diseases associated with the aberrant activation of these receptors.

Career Highlights

Throughout his career, Zimmermann has worked with renowned companies such as Bristol-Myers Squibb Company and Arvinas Operations, Inc. His positions in these organizations have allowed him to contribute significantly to research and development in the pharmaceutical industry, focusing on innovative therapies that target dysregulated proteins.

Collaborations

Zimmermann has collaborated with key professionals in his field, including Xiaopeng Sang and Mark D. Wittman. These partnerships have facilitated the interdisciplinary synergy required to drive forward innovative solutions in drug design and development.

Conclusion

Kurt Zimmermann stands out as a leading inventor dedicated to creating groundbreaking therapies through targeted protein degradation. His extensive patent portfolio exemplifies his commitment to improving patient outcomes and advancing scientific knowledge in the realm of pharmacology. His contributions not only address existing medical challenges but also pave the way for future innovations in treatment methodologies.

This text is generated by artificial intelligence and may not be accurate.